Updates from Syncona and our portfolio companies
An animation explaining what gene therapy is, how it has evolved over 50 years and the goal of providing a long-term cure for patients who receive treatment.
Freeline Data Update at EAHAD conference 7 Feb 2020 – watch our video overview
Syncona’s Chief Investment Officer, Chris Hollowood and Syncona Partner, Dominic Schmidt, provide an introduction to gene therapy, a field where Syncona has developed deep domain expertise and built a strategic platform.
Syncona’s Chief Investment Officer, Chris Hollowood and Syncona Partner, Dominic Schmidt explain how Syncona has built a globally leading platform of unpartnered gene therapy assets.
Syncona’s Chief Executive, Martin Murphy and Syncona Partner, Elisa Petris describe Syncona’s strategy to Found, Build and Fund global leaders in life science.
Syncona’s Chief Executive, Martin Murphy and Syncona Partner, Elisa Petris talk through the process for founding our innovative cell therapy company, Quell Therapeutics.
Syncona speaks to one of Quell Therapeutics’ academic founders, Alberto Sanchez-Fueyo, about his career, the potential of T-regulatory cells and his vision for the business.
Syncona speaks to Achilles Therapeutics' clinical founder Charlie Swanton about his career, the advent of immunotherapy, and what he wants Achilles to achieve.